Physician profile
James Milite
NPI 1144210873
$398.52
in general payments reported to CMS, 2019-2025
10 companies · $53.93 in 2025
The $53.93 reported for 2025 was less than what a typical Ophthalmic Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.57 · 2020: $41.26 · 2022: $48.28 · 2023: $106 · 2024: $83.21 · 2025: $53.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $243.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $106.27 | 2023 | Tecnis Iol |
| Tarsus Pharmaceuticals, INC. | $57.79 | 2024-2025 | Xdemvy |
| Carl Zeiss Meditec, INC. | $51.44 | 2019 | |
| Amgen INC. | $47.14 | 2024 | Tepezza |
| Oyster Point Pharma, INC. | $33.28 | 2022 | |
| Abbvie INC. | $32.08 | 2022-2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $26.87 | 2020 | |
| Sight Sciences, INC. | $15.13 | 2025 | Sion Surgical Instrument, Omni Surgical System |
| Aerie Pharmaceuticals, INC. | $14.39 | 2020 | |
| Boston Scientific Corporation | $14.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Milite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.